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from 48 countries, and in 44 organisations of cord 
blood banks from 30 countries [3]. 
According to statistics from the Blood Marrow Donor 
Worldwide annual report the number of unrelated 
 donors, stem cell donor registries and publicly stored 
cord blood units has been growing each year. However, 
the number of donors is still largely insufficient to cover 
the number of HSC transplants needed, in particular 
for patients who have a rare HLA type [1]. In relation 
to the Swiss context the need for finding more donors 
has been seen as a priority given that Switzerland 
is at the bottom of international rankings with just 
2.8 donor per 1000 inhabitants [2]. Consequently, 
transplantations registries, physicians as well as 
 donors and patient associations have all searched for 
strategies in order to increase the number and diver­
sity of available stem cell transplants. In Switzerland 
the Swiss Transfusion SRC, division Swiss Blood Stem 
Cells (SBSC), is the national organisation for all matters 
relating to blood stem cells, from registration to search 
of suitable donors worldwide [2]. 
In the current article we will analyse from an ethical 
perspective different strategies to increase unrelated 
HSC donation and provide recommendations regarding 
their ethical acceptability. Direct donation to siblings 
will not be included since ethical issues are not com­
pletely the same as with unrelated donation. We will in 
particular examine (1) whether ethical arguments exist 
to invest efforts and resources in certain types of HSC 
banks rather than in others, and how different stra t­
egies may be used to increase donation, such as (2) 
 tailored information about risks and benefits, (3) moti­
vation enhancement strategies to donate, in particular 
avoiding last minute withdrawal of donors that puts 
at risk the life of the recipient, (4) advertising, (5) un­
related donation limited to certain groups of recipients, 
(6) payment for donation and (7) additional non­mone­
tary benefits.
Scarcity of donors and transplantable  
material: particularities of HSC donation  
in comparison with other types of tissue  
or organ donation
Strategies to increase the quantity of material suitable 
for donation have been discussed in different contexts 
ranging from living or cadaver organ donation to vari­
ous types of blood product donations. Even more than 
for other types of transplants, in HSC transplantation 
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Introduction: 
The need for haematopoietic stem cell 
donation
Many haematological diseases are life­threatening and 
can only be cured if the patient undergoes transplanta­
tion of haematopoietic stem cells (HSC). In order to 
 improve prognosis and to decrease risks, the degree of 
human leukocyte antigens (HLA) match between donor 
and recipient is very important. There are cases where 
it is not possible to find a donor residing in the same 
country for an affected patient waiting to receive HSC 
transplantation. Hence, in order to save lives, interna­
tional collaboration between various donor registries 
from different countries is paramount. 
The benefit of international cooperation is proven by 
the fact that in 2008, of the more than 11 500 patients 
who received a haematological stem cell transplant 
from an unrelated donor internationally, more than 
44% of those patients were treated using a stem cell 
 donor or cord blood unit that came from a different 
country than the patient [1]. Regarding the Swiss con­
text, around 95% of Swiss patients receive blood stem 
cells from a donor abroad, whereas about 90% of all 
Swiss donations go to patients abroad [2].
Unrelated HSC transplants can be obtained from cord 
blood banks or adult stem cell donor banks. At present, 
there are around 19.4 million registered unrelated 
 donors worldwide, in 65 stem cell donor registries 
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If donors are motivated by intrinsic or extrinsic altru­
ism [7], the «warm glow» could be higher in proportion 
of the taken risks as well as to the created benefit, 
 similar to the fact that having risked one’s own life to 
save another person from drowning might make the 
life­saver happier than having altruistically given one’s 
sandwiches to a hungry beggar with the side effect of 
staying hungry oneself for the evening. It is also not 
 excluded that some donors might feel happier if they 
knew that they have saved the life a young child as 
compared to saving the life of an eighty year­old adult. 
While the degree of benefit might influence willingness 
to donate, we will discuss later whether this has an 
 influence on the ethical aspects of donations.
We conclude from the existing similarities between 
HSC donation as compared to other types of tissue and 
organ donation that it is reasonable to take into 
 account data obtained through studies of strategies 
to increase other types of donation. In Switzerland a 
recent recruitment strategy has established closer col­
laboration with the regional blood transfusion services, 
in order to learn from their experience with donation 
[2]. However, given the particularities of HSC donation, 
there are specific aspects to take into account in the 
ethical analysis. In order to be able to analyse whether 
consequences of different strategies to increase dona­
tion are acceptable, specific data concerning this type 
of donation are useful, and perhaps even necessary.
Increasing efforts and resources to enlarge 
HSC banks
Different types of HSC banks imply different types of 
risks related to donation as well as different types of 
costs to maintain the banks and registries and varying 
benefits for future recipients of the transplantable 
units. As far as risks to donors are concerned, un­
related umbilical cord blood banking [8] and banks 
that store stem cells derived from aborted foetuses, e.g. 
to obtain foetal liver HSC, have the advantage to imply 
a lower risk. Indeed, «a bank of fetal liver HSC will 
prove useful in treating a variety of genetic diseases 
 before birth by in utero HSC transplantation» [9, 
p. 394]. In both cases, the stem cells are derived from 
sources such as the placenta or aborted foetuses that 
would have been thrown away in most cases, and there 
is no harm to the mother, her baby or the mother who 
underwent abortion. It would therefore seem straight­
forward from an ethical point of view to increase 
 efforts in building these types of blood banks, while 
 ensuring adequate informed consent of mothers [8, 9].
2
 
the specific match between donor and recipient is 
very important for prognosis. Another characteristic 
of HSC transplantation is that repeated donations may 
be needed to save the life of the patient.
1
 A particular 
aspect of this type of living donation is, that in the case 
of unrelated donation, there is a considerable time gap 
between the moment a donor agrees to be in a registry 
and the actual moment of donation [4]. On average a 
possible donor has been in the registry for 8 years [5] 
before he or she is approached because a matching 
 patient has been found. This implies that donors may 
have signed up to be registered but have forgotten that 
they once agreed or changed their mind and either 
 refused donation or refuse repeated donation. Strate­
gies to increase donation have to take into account the 
 particularities of HSC donation. They also have to take 
into account availability of resources, evidence, exter­
nal regulations and, both donors and receivers expec­
tations [6]. 
Ethical considerations related to increasing the num­
ber of donors and donated units are shaped by the 
 different risks, inconveniences and benefits for donors. 
Risks for donors depend on of the type of the trans­
planted entity. HSC donation can be situated on a 
 middle ground between blood donation and living 
 organ donation, e.g. of a paired organ such as kidneys. 
Risks and inconveniences of HSC donations for donors 
are not as low as they are for blood donation. Indeed, 
HSC donation requires either minor surgery to obtain 
bone marrow, or the treatment of the donor with 
 granulocyte colony stimulating factor (G­CSF) in order 
to be able to harvest enough stem cells from the periph­
eral blood (PB). The risks of G­CSF have so far not 
yet been fully determined, although short term risks 
seem to be rather low. On the other hand, living solid 
organ donation, e.g. kidney donation, has clearly more 
serious side effects than the donation of HSC because 
of the fact that the lacking organ will not regrow even 
if on the functional level a single kidney is sufficient to 
permit long term survival of the donor.
The words stem cells have a tendency to trigger high 
ethical awareness. It is therefore important to examine 
whether the fact that the transplant consists of stem 
cells creates particular concerns and distinguishes this 
form of transplantation from others. In this regard it is 
crucial to remind ourselves that most ethical concerns 
in the stem cell debate are related to human totipotent 
stem cells that may give rise to a human being. At pres­
ent, it is not possible to reprogramme adult somatic 
stem cells into totipotent cells. As such we do not see 
any reason to treat the donation of HSC differently than 
the donation of other somatic cells. Nonetheless, if 
 reprogramming of somatic cells became a reality, then, 
it is likely that this will create new ethical problems for 
various adult cell donations, not only HSC donation.
In relation to the benefits for donors that might result 
from unrelated donation, it is difficult to say whether 
these are specific to the type of transplant or recipient. 
1 However, according to the Swiss Blood Stem Cell web page «Blood 
stem cells cannot be donated regularly but, if at all, usually only 
once or twice in a lifetime» [www.sbsc.ch/in­case­you­donate/ 
 (accessed 2.4.2012)]. 
2 In Switzerland there are 2 public banks with which the SBSC works 
closely, 1 in Basel and 1 in Geneva, in which more than 3000 units 
are currently stored and made available to patients [2].
 Bioethica Forum / 2012 / Volume 5 / No. 3 94
Focus: blutstammzellspende / le don de cellules souches du sang / blood stem cell donation
that the donor’s decision is free and not unduly coerced 
[14], it remains open to discussion how much informa­
tion is adequate and how much choice donors should 
have. Should they be allowed to choose between BM 
or PB HSC donation because that might increase their 
motivation to donate? Or should donors rather be 
 protected against bad choices that imply higher than 
necessary risks to them or to the recipients? BM dona­
tion has been carried out for more than 30 years and 
its risks are well known. It requires hospital admission 
for 1–3 days and absence from work is usually 7–10 
days. Contrary to PB HSC harvesting, no administra­
tion of HSC stimulating drugs is necessary [13]. Data 
in the Cochrane Central Register have been obtained 
primarily from adults, and comprise 6 relevant ran­
domised controlled trials that compared allogeneic BM 
and PB SC donations’ safety. Both physical and psycho­
logical side effects of the two methods were reported 
[13]. While in the BM group there were overall more 
(56%) adverse events observed than in the PB group 
(44%), most of them were minor side effects such as 
pain at the surgical site and asthenia following anaes­
thesia. The data from the European Group for Blood 
and Marrow Transplantation analysis, performed 
1993–2005, seem to indicate that BM donation is over­
all safer as far as serious side effects are concerned. 
Five fatal events were observed, of which one con­
cerned a BM donor and the other four PB donors. 
Among the 37 reported serious adverse events only 
12 took place after BM donation, compared to 24 that 
occurred in a PB donor (P <05) [13]. Some fear that 
 G­CSF can theoretically increase the risk of haemato­
logical malignancies, however studies have not found 
evidence for that, but follow up has been short [15]. 
In the case of children the risks of short and long­term 
G­CSF administration are even less well established 
[15–17]. Risks vary across different subgroups of 
 donors which confirm the «necessity of accurate atten­
tion to donor selection and evaluation in bone marrow 
donation» [13, p. 2192]. 
Up to now countries have reacted differently to the 
available evidence. In France, the donation of PB stem 
cells is forbidden for minors, because in vivo blood 
treatment before a donation is only allowed in adults. 
For the latter, age limits exist that vary according to 
 relationship between donors and recipients. PB HSC 
donation in France is allowed for family members until 
the age of 60, but for unrelated donors only until the 
age of 50. Unrelated donors may however give BM  until 
the age of 60 [12]. According to Esperou [12], in 
 Belgium PB HSC donation is allowed for minors who 
However, this solution has two major drawbacks. 
First, both types of banks contain a limited amount of 
material from the same donor. While for some indica­
tions, cord blood and foetal stem cells are particularly 
suitable, they are insufficient for other transplantation 
indications of HSC.
3
 In relation to this it is important to 
mention that in recent years there has been «a signifi­
cant increase in and promising clinical results with 
‹double­cord› transplants (transplants from 2 different 
cord blood donors) or even ‹multi­cord› transplants for 
adults» [2, p. 306].
Second, costs for the establishment and maintenance 
of umbilical cord blood (CB) banks for unrelated dona­
tion are several times higher than the costs related to 
HSC donation of living children or adults, for example 
due to the necessity to store the blood and/or its prod­
ucts until a matching recipient is found which may take 
several years [10, 11].
4
 This raises the question, as to 
how much society should pay in order to increase the 
number of cord blood stem cell units and to permit the 
storage of stem cells obtained without significant risks 
to donors. Strategies to increase donation of placenta 
derived stem cells have been examined in Switzer­
land.
5
 The Swiss study showed «a high degree of satis­
faction of unrelated umbilical CB donation for banking 
in women 6 months after delivery» [8, p. 604]. The 
main barriers for donation seemed to have been that in 
spite of a «well­performed and detailed informed con­
sent procedure» a significant proportion of mothers 
 remained concerned about improper use of the blood 
cells, mainly genetic testing or experimentation [8]. 
The data show that public education and adequate 
counselling of pregnant women and their partners are 
crucial to improve strategies to obtain more available 
stem cell units. It is worth noting that, the described 
strategies to increase this type of HSC donation are 
fully ethically acceptable if not ethically required, de­
pending on the way how society balances the allocation 
of financial means for this type of banking in compari­
son to other health care interventions.
Information of donors about benefits  
and risks of unrelated HSC donation
During the past years, an increasing percentage of HSC 
have been obtained from peripheral blood (PB), while 
the percentage of stem cells taken directly from the 
bone marrow (BM) decreased proportionally [12]. For 
example, in Italy in 2008, 1467 allogeneic transplants 
were performed, of which 636 (43.4%) were obtained 
from an unrelated donor, 188 from BM and 323 from 
PB [13]. The way in which HSC are obtained, as well as 
the way and type of information provided to donors 
about benefits and risks, is likely to influence a person’s 
willingness to donate. While it is not controversial that 
voluntary and informed consent of donors is the ethical 
and legal prerequisite for donation in order to ensure 
3 Moreover, this type of HSC transplantation as Thomas Bart argues 
“has  frequently become the ‘last resource’ because of the pos sibility 
of a higher mismatch due to the relative immaturity of its blood 
stem cells” [10, p. 141].
4 Other costs involved are those in relation to treating and typing [9]. 
5 The study required not only obstetric clinics to devote time and re­
sources to systematic recruitment of donors, but relied to a notable 
extent on thorough information of donors and the public.
 Bioethica Forum / 2012 / Volume 5 / No. 3 95
Focus: blutstammzellspende / le don de cellules souches du sang / blood stem cell donation
Based on the donors’ autonomy rights, the WMDA 
 decided that it is ethically not acceptable to force do­
nors in any way to reconsider the withdrawal by legal, 
economical, moral, emotional or other means. The 
 donor must not be made legally responsible for any 
consequences her/his withdrawal has on the patient 
[21]. This balancing of donor’s autonomy versus benef­
icence to the recipient can also be motivated by conse­
quentialist reasons. It could increase donors’ willing­
ness to sign up for the donor process because they do 
not need to fear to be at any time forced into donation. 
The obligation to protect recipients is instead conferred 
to the donor registry. It is both the transplant centre 
and the donor registry that have the «responsibility 
to avoid a situation where a donor withdraws from 
the procedure at a critical time». In addition to this, 
to avoid detrimental withdrawal, the donor registry 
«should do whatever is possible to identify, as early as 
possible, problems or doubts that might interfere with 
the donor’s ability to donate» [21, p. 226]. This implies 
that for uncertain donors early ways to opt out must be 
in place, where there is no loss of face. 
The education process must be such that a donor 
cancellation, for any reason, is not disastrous or 
depressing, but rather easily understandable and 
acceptable to the donor [21, p. 226 (emphasis 
added)].
As long as there are no other available data, one has to 
assume that the highest number of donors and least 
withdrawals are not obtained through unethical pres­
sure or persuasion, but through good communication, 
trust, and understanding [21], because this helps 
the donor to cope with possible later stressful events. 
In Switzerland a successful strategy to increase the 
number of donors has been the possibility for donors to 
register online [2]. The website www.bloodstemcells.ch 
was set up for this purpose. This motivation enhance­
ment measures taken by Switzerland also include 
 machine­readable forms and novel sampling methods 
that make the sampling less invasive and which allow 
donors to carry the blood sample collection at home. 
In a similar manner, new donors are «no longer tested 
for blood group and infection markers» [2, p. 303]. 
These are now only carried out if the person is invited 
for a compatibility test. While Switzerland has already 
shown a commitment with finding strategies to in­
crease donation, we recommend that in order to keep 
with ethically correct motivation profiles it is necessary 
to provide donors with information and education that 
make them fully aware about their rights and any limi­
tations (if any) of the procedures and therapies them­
selves. The main goal is to motivate donation decisions 
that are not based on feelings of obligation, but rather 
on a mature sense of responsibility built upon objec­
tive, nonbiased, and thorough information, including 
the fact that there is a reasonable possibility of multiple 
or subsequent donation requests. In this respect it 
donate to a sibling, in Canada it is also allowed for 
 unrelated donation, but only the second time such 
 donation takes place and not the first time. In Japan, 
only donation to a family member but not unrelated 
 donation may be done using PB [12]. 
A number of conclusions can be made based on these 
data. First of all, since the benefit of unrelated donation 
depends to a great extent on international collabora­
tion in order to find the best possible match, the varia­
tion between countries as to acceptable risks is likely to 
undermine the trust of donors and may have a negative 
impact on their willingness to donate. The first impor­
tant step to increase donation would therefore be to 
harmonise recommendations and policies internation­
ally. The SBSC database is required by law to report all 
«transplant outcomes and to adhere to the comprehen­
sive quality management system JACIE (www.Jacie.
org)» [18, p. 327]. The SBSC data registry, which 
unique feature is its capacity to capture 100% of all 
HSC transplant in Switzerland performed in public 
 institutions, can be seen as a good international exam­
ple for the establishment of good quality control mech­
anisms.
Second, since risks and benefits of BM and PB HSC 
 donation are similar, although not identical, full and 
unbiased information of donors is likely to have the 
best effect in the long run to maintain their motivation. 
In the absence of significant negative consequences on 
the recipient following from the method of donation, it 
does not seem to exist any justified reason for pater­
nalistic limitation of donors’ choices, especially if this 
 paternalism could have a negative influence on the 
willingness to donate. However, more studies are 
 urgently needed to obtain more data on the effect of 
choice on motivation to donate HSC.
Motivation enhancement strategies to 
donate, including prevention of last minute 
withdrawal of donors that puts at risk  
the life of the recipient
A specific problem to unrelated HSC donation lies in 
the fact that a time gap exists between the first motiva­
tion to join a donor registry and the final decision to 
 actually donate, usually only several years later. The 
World Marrow Donor Association’s (WMDA) standards 
give precedence to the donors’ right to withdrawal 
even if this might entail serious and even fatal conse­
quences for the recipient [19]. 
Although the primary responsibility of the registry 
is in protecting the donor and ensuring their 
safety, the registry must ensure that the donor is 
aware of the serious, and potentially life-threaten-
ing, consequences to the recipient if the donor 
chooses to withdraw at any time, but particularly 
if this is after the recipient’s pretransplant condi-
tioning has commenced [see (20). p. 833]. 
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their families. An example is the case of Sabine Geisen­
hofer, the young mother of a one year­old child who 
 advertised through youtube and online journals her 
need for a donor. As a result of the campaign, 1572 
 individuals agreed to HLA typing and to be registered 
for future donation. MS. Geisenhofer’s child was finally 
transplanted using a donation found through world­
wide connected registries as no match was found 
among the new HLA typed volunteers. However, it is 
worth noting that all the newly found  potential 
donors agreed to donate to other patients in need if 
they were found not to be a suitable match for the 
S. Geisenhofer’s child [24–26]. 
In conclusion, whether any specific form of advertising 
is acceptable or not, will depend on three major as­
pects. First, information provided must be correct and 
not hide any risks involved in donation. Second, there 
should not be any emotional pressure put on donors by 
the registry. On the other hand, patients and their fam­
ilies have the right to describe their own stories and to 
make them known publicly. Third, recruitment where 
donors learned about HSC donation through knowledge 
about a particular patient should be accompanied by 
research on the overall reliability of such  donors.
Unrelated donation limited to certain groups 
of recipients
In Switzerland, too, the pressure is growing to find new 
HSC donors. Possible donors in Switzerland have indi­
cated their concern to want to know who gets their 
stem cells. Such questions were integrated in a recent 
research project financed by the Swiss National  Science 
Foundation. Does it matter to donors if patients are 
 responsible for their illnesses? Can donors withdraw 
their donations in such cases? What happens if a donor 
has been assured that his donation will save small 
 children but is actually used for a 70 year­old patient 
[27]?
While direct donation to a relative is a well­established 
practice to ensure optimal HLA matching, directed 
 donation to non­related people has been discussed con­
troversially [4, 28–31]. One argument against this prac­
tice is that donor protection is jeopardised because 
knowing the recipient might create pressure on the 
 donor. It is also argued that incentives, such as pay­
ments, may be used by patients, usually in a clandestine 
way if they are illegal in the country. Another common 
argument is that allowing donors to limit their donation 
to a certain group of patients would also lead to unfair 
discrimination. Requests risk to be made based on 
 racism, blaming of certain patient groups, or age re­
lated preference. Such discrimination of mostly vulner­
able groups has a negative influence in society because 
it favours the acceptance of a discriminatory policy. 
It seems likely that in the end overall altruism in 
society could decrease with a negative  effect on dona­
seems a sensitive measure that the WMDA requires 
centres to document not only informed consent as such 
but to indicate in detail how the donor was counselled 
[21]. Or as it is case of Switzerland, the fact that donors 
are followed up after donation can also be seen as a 
 motivation feature for individuals thinking about the 
possibility of becoming donors.
Advertising
Advertising is controversial because of different 
 problems. It might use emotions to unduly pressure 
possible donors towards accepting to be in a registry 
and to donate. In addition, it is feared that donors 
who respond to emotionally loaded advertising are 
less reliable when it comes to actual donation than 
those that make the decision outside any emotional 
context. However, many donors are motivated by the 
knowledge of a more or less close person who suffered 
from serious disease requiring any form of transplan­
tation. Also, without advertising referring to actual 
cases of patients, many possible donors might not even 
be aware of the stakes and not able to imagine the 
 benefits HSC donation has for the life of patients. 
Recently, a case from Spain has triggered much debate 
about the limits of advertising. In 2011, the Spanish 
National Transplant Organization (ONT) made a num­
ber of allegations concerning the activities of the Ger­
man Bone Marrow Donor registry (Deutsche Knochen­
markspenderdatei, DKMS) in Spain [22]. ONT alleged 
that DKMS activities in Spain were illegal  referring to 
recommendations given by the Spanish Commission 
for Transplants and Haematological Stem Cells. Ac­
cording to these recommendations, donors should 
preferably not be won by reference to a specific patient 
because such donors would be less reliable. In addi­
tion, the chance to find a matching donor for these 
 specific patients would be too small. DKMS defends 
their practice by indication that the recommendations 
are not legally binding and that they have good reasons 
to contradict the allegations. They claim that their 
 reasons are in line with international medical practice, 
for example WMDA standards, but also consistent with 
evidence based scientific literature [23]. The CEO of 
DKMS has defended its practice based on the data they 
have obtained during the past 20 years which «can 
prove in numbers that donors registered with refer­
ence to a specific patient are not less reliable than 
other donors; in fact, DKMS donors are by far the most 
reliable donors worldwide» [23, p. 2]. Through adver­
tising using individual cases, therefore the sum of all 
donors who agree to register increases and «leads to a 
broadening of the general donor base» [23]. Moreover, 
DKMS argues that they inform all registered donors 
that they are not registered for only one patient but for 
all patients in need and that their advertising activities 
usually build on the strong engagement of patients and 
 Bioethica Forum / 2012 / Volume 5 / No. 3 97
Focus: blutstammzellspende / le don de cellules souches du sang / blood stem cell donation
their own chances to find a well­matched transplant. 
Such policies tend to be unfair overall since most  com­ 
plex groups are not homogenous and the ‘punishment’ 
would be unfair for those members of the countries 
who donate without limitations. Here again, an ethical 
way to deal with such claims is better information. The 
public must know about the necessity of  international 
solidarity and societies should increase all efforts 
against in­country racism and unfair discrimination.
Payment for donation
WMDA Standards are adamant that donors «must 
not be paid for their donation, but may be reimbursed 
for expenses incurred during the donation process, for 
example, time lost from work or travel to the collection 
center» [20, p. 832]. The reasons for such a policy are 
generally based on a consequentialist approach and 
most data available about the consequences of pay­
ments stem from studies about blood donation. Already 
in the 1970 the famous study of Titmuss [32, 33] 
 presented data indicating that payment is likely to 
‹wash out› altruistic motivation and therefore overall to 
decrease donation frequency as well as the quality 
of the donated blood. Similar evidence comes from sev­
eral additional studies [7, 34, 35] which speak in favour 
of perverse effects of financial rewards and motivated 
the World Health Organization (WHO) to recommend 
that all blood donations should come from unpaid vol­
untary donors [7]. 
While the international position on payment has in 
general joined the WHO recommendations, offering 
 reimbursement of costs to donors for travel and lost 
work time, some countries are offering payment to 
blood donors [7]. We defend the position that payment 
should only be offered as part of randomised studies 
that intend to obtain more evidence of the conse­
quences of payment on the donation of HSC. Unless 
strong evidence indicates clear benefit of payment on 
willingness and reliability to donate HSC, there is no 
justification today to use monetary benefits in this field. 
Hence, based on current evidence, it is ethically the 
best option to forgo monetary benefits because of the 
overall benefits such policy has for recipients.
Creating additional non-monetary benefits
Donation can be due to intrinsic motivation, the so­
called pure altruism, or due to extrinsic motivation 
which includes an inner ‹warm­glow› or moral satisfac­
tion. A recent study involving a large sample represent­
ative of 15 European countries showed that the results 
«are consistent with the idea that altruistic behaviour 
can be incentivised as long as the rewards do not con­
ceal the identity of the blood giver as a donor» [7, p. 2], 
meaning as long as donors do not feel ‹paid›. Accord­
tion altogether, apart from the fact that the administra­
tion of such selective donation  requests risk to be an 
 administrative nightmare creating significant additional 
costs. Apart from such con sequentialist arguments, it 
must also be said that even if such selective donation 
were proven to increase the number of donations, it 
would be contrary to the prohibition of  unfair discrimi­
nation which is part of the human rights framework 
strongly enshrined in modern societies.
It should be noted that the WMDA has concentrated its 
efforts on volunteer unrelated donors. «Donors must be 
willing to donate on behalf of any patient being treated 
in any part of the world» [20, p. 832]. Registration of a 
donor implies a general offer to be available for any 
 patient in need of a haematopoietic stem cell transplant 
anywhere in the world, «irrespective of the patient’s 
age, gender, nationality, creed or ethnicity» [19, p. 539]. 
Understandably, the best possible match can only be 
found, if all registries are internationally linked and do­
nors available for any kind of patient in need, based 
only on HLA compatibility or other clinically  relevant 
characteristics. The principle of non­selective donation 
is therefore accepted worldwide for unrelated HSC do­
nation and regarded as an ethically acceptable practice.
A separate issue is related to the principle of anonym­
ity, a widely held position that aims to avoid abuse, 
such as donors asking for compensation after finding 
out to whom he or she donated their HSC. WMDA is 
concerned about possible pressures if the principle of 
anonymity is breached, thus, it recommends «that the 
donor center/registry should not inform a donor about 
the patients’ diagnosis, gender, age, and similar kinds 
of facts» [21, p. 227]. In addition concerns exist that 
motivation of donation will decrease if the donor learns 
about possible negative outcomes of the donation, as 
they might feel that the pain and effort of the donation 
was ‘wasted’ [12]. General information about the prog­
nosis of the patient may eventually be given, but only 
after a certain time and with great caution. Shaw and 
colleagues underline that registries must have a writ­
ten policy listing the conditions under which donors 
and recipients might be informed of each other’s iden­
tity [20]. Since it is not rare that donors will be asked 
for subsequent donations, it is important that registries 
adopt policies which guarantee that donors are not put 
under undue pressure because donor anonymity has 
been abandoned, perhaps even at the request of the 
donors themselves. 
If it were true that in some parts of Switzerland a sig­
nificant number of possible donors refuses donation 
 because of fear that their HSC might be given to for­
eigners, old patients or other groups that they do not 
value in the same way as others, what would be the 
possible consequences? A likely consequence is that 
 donor groups who donate only in a selective way, for 
example less altruistic countries as a whole, will also 
only receive transplants from the same selected groups, 
meaning from their own country, i.e. they will decrease 
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increase the frequency, reliability and quality of dona­
tions. Donor and patient privacy should be maintained 
and selective donation should be excluded or limited. 
Providing monetary benefits for donation, outside jus­
tified reimbursements, would increase social injustice 
and probably decrease safety; however some other 
forms of non­monetary ‘reward’ are acceptable and so 
far underused.
A balance needs to be made between safety, efficiency 
and costs of different forms of HSC donations. The best 
way to increase donation is not through pressure, but 
through transparency and best information and advo­
cates of donors. Last but not least, in order to be able 
to conclude in a stronger way on the ethical aspects of 
different strategies to increase donation, more empiri­
cal research on the consequences of such strategies is 
needed.
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Zusammenfassung
Ethisch vertretbare Möglichkeiten, die Spendebereit-
schaft für Blutstammzellen zu erhöhen 
Ethische Aspekte des Umgangs mit Spenden von 
menschlichem biologischem Material werden seit lan­
ger Zeit diskutiert, angefangen bei der Organspende 
bis hin zur Gewebe­ und Zellspende. In diesem Zu­
sammenhang ist eine zentrale ethische Frage, wie die 
Spendebereitschaft auf sichere und ethisch vertret­
bare Weise erhöht werden könnte. In diesem Beitrag 
konzentrieren wir uns auf die Frage, wie die Be­
reitschaft zur nichtverwandtschaftlichen Spende von 
 Blutstammzellen auf ethisch vertretbare Weise erhöht 
werden könnte, wobei Fragen der spezifischen Infor­
mation über Nutzen und Risiken sowie nichtmonetäre 
Vorteile im Vordergrund stehen. Darüber hinaus fragen 
wir, ob bestehende Praktiken zur Erhöhung der 
 Spendebereitschaft, beispielsweise der Einsatz für be­
stimmte Typen von Blutstammzellenbanken, Bezah­
lung, Werbung und gezielte Spenden, ethisch vertret­
bar sind oder nicht. Schliesslich formulieren wir einige 
Empfehlungen, um einerseits die Debatte in dieser 
Frage voranzubringen und andererseits die ethisch 
vertretbaren Praktiken der Blutstammzellenspende in 
der Schweiz zu fördern, wobei diese Empfehlungen 
durchaus auch weltweit angewendet werden können. 
Résumé
Des méthodes éthiquement acceptables pour aug-
menter les dons de cellules souches hématopoïé-
tiques 
Les enjeux éthiques du don de matériel biologique 
 humain – du don d’organes au don de tissus et de 
ing to this study, as well as other findings from behav­
ioural economics [14], providing non­monetary bene­
fits to possible donors of HSC will maintain altruistic 
motivation while at the same time increasing frequency 
of  donation. Buyx [14] reminds us that these findings 
are not new, nor really surprising. What she finds sur­
prising is that these findings «have not been put to 
use systematically to help increase … donation» [14, 
p. 335]. Several effects are known to influence human 
choices such as the framing effect which means the 
way in which options are presented, the conformity 
 effect, which indicates that independent from rational 
reasoning, «people have an in­built, automatic desire 
to behave in the way others behave» [14, p. 335] and 
the incentives effect. Incentives will influence people’s 
choices if they are tailored to people’s motives and 
combined with framing or information about what 
 others do. Such measures are effective without being 
coercive [14]. It is perfectly justified for donor centres 
to use insights into behavioural psychology to affect 
 decisions – without this meaning that one makes peo­
ple agree to donation against their will. Incentives 
might be necessary throughout the entire time a donor 
is in the registry. This requires regular, for example 
 annual contacting of donors and which also provides 
the opportunity for donors to maintain or reconsider 
their motivation in advance which in turn increases 
their reliability. Among ethically acceptable incentives 
that have been discussed depending on the group that 
is addressed are vouchers for songs on iTunes, for a 
wellness class or a restaurant; mobile phone ring tones 
or mobile phone credits; video game bonuses; tickets to 
the theatre, museums, lectures; a mark of public recog­
nition (e.g. donors’ names being put on public display 
on TV, online, in a newspaper, read out in a radio 
show or at some community event); donor­exclusive 
T­shirts or events to which only donors can buy tickets 
or can buy them first [14].
Conclusions: ethical ways to increase  
HSC donation
There is an urgent need to increase HSC donation. 
Not all strategies to increase donation are acceptable. 
Existing empirical data on motivation need to be better 
applied to the practice of HSC donation. We have 
shown that deontological arguments referring to the 
respect for donor autonomy as well as consequentialist 
arguments based on data about benefits and risks of 
certain strategies lead in most cases to the same con­
clusions. Advertising is ethically acceptable as long as 
certain conditions are maintained. This includes that 
advertising with reference to individual receivers is 
 acceptable under certain circumstances. The donor 
must be made fully aware of the favourable and ad­
verse outcomes of HSC donation. Unbiased and com­
plete information about risks and benefits is likely to 
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 cellules – sont discutés depuis longtemps. Un des soucis 
soulevés dans ce contexte est l’identification de  mé ­ 
thodes sûres et éthiquement acceptables d’augmenter 
ce type de dons. Dans cet article, nous abordons quel­
ques méthodes éthiquement justifiées d’augmenter le 
don non apparenté de cellules souches hémato poïé­
tiques, comme l’information sur mesure sur les risques 
et bénéfices, et les bénéfices non financiers. Nous  dis­ 
 cutons également les aspects éthiques de  pratiques ac­
tuelles comme l’investissement d’efforts et de ressour­
ces dans certains types de banques cellulaires, la pub­
licité et le don dirigé. Nous concluons avec quelques 
 recommandations susceptibles de faire avancer le dé­
bat dans ce domaine, et nous soutenons des pratiques 
éthiquement justifiées dans le domaine du don de cellu­
les souches hématopoïétiques en Suisse, qui pourraient 
également être employées à l’échelle mondiale.
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